Physician

Ajeet Gajra, MD

According to 2025 Medicare claims, Ajeet Gajra, MD (NPI: 1538197975) practices hematology/oncology in the Syracuse, NY market, with the plurality of this provider's patient population coming from Onondaga, NY. This provider's primary affiliated billing organization is HEMATOLOGY-ONCOLOGY ASSOCIATES OF CNY, PC (NPI: 1902885429; TIN: 161184100) and primary practice location at 13057-9248. Gajra is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Gajra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 588 traditional Medicare patients, billed 38,107 HCPCS/CPT codes, and received $582,412 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 242 prescription claims across 73 beneficiaries totaling $729,793 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 46 claims. Open Payments data shows 28 records totaling $297,749. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,067,498 to $582,412. Similarly, Part D prescription costs have moved sharply higher in recent years, from $302,232 to $729,793. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,670 and ending at $1,068.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	383	67,765	$1,067,498
2016	324	47,186	$833,734
2017	234	21,606	$616,288
2018	76	10,371	$188,400
2019	61	8,715	$85,062
2020	94	18,628	$294,841
2021	115	20,100	$321,057
2022	254	4,575	$77,920
2023	652	85,599	$1,221,226
2024	588	38,107	$582,412

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	79	320	$302,232
2016	75	271	$533,724
2017	61	244	$402,552
2018	N/R	34	$2,624
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	32	77	$148,339
2023	75	263	$906,641
2024	73	242	$729,793

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	64	$4,061
2016	N/R	N/R	N/R
2017	N/R	28	$936
2018	N/R	24	$1,102
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	14	18	$11
2024	N/R	46	$963

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	261	546	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	238	298	$64
80053	Blood test, comprehensive group of blood chemicals	263	754	$10
36415	Insertion of needle into vein for collection of blood sample	272	947	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	279	1,038	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	11	307	$149,122
Gabapentin	Gabapentin	12	360	$140
Paroxetine Hcl	Paroxetine Hcl	13	510	$99
Prednisone	Prednisone	22	672	$89
Mirtazapine	Mirtazapine	13	360	$30

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	12	$587
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$213
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	18	$17,734	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	10	$280,015	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ajeet Gajra, MD?

Tedicare shows public-source Medicare data for Ajeet Gajra, MD (NPI 1538197975), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ajeet Gajra, MD have ACO affiliation data?

Ajeet Gajra, MD is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Ajeet Gajra, MD?

Ajeet Gajra, MD is linked to HEMATOLOGY-ONCOLOGY ASSOCIATES OF CNY, PC (billing NPI 1902885429) in the available physician profile data.

Does Ajeet Gajra, MD have Open Payments data?

Ajeet Gajra, MD has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.